CN110754664A - Composition for preventing osteoporosis - Google Patents
Composition for preventing osteoporosis Download PDFInfo
- Publication number
- CN110754664A CN110754664A CN201911235880.XA CN201911235880A CN110754664A CN 110754664 A CN110754664 A CN 110754664A CN 201911235880 A CN201911235880 A CN 201911235880A CN 110754664 A CN110754664 A CN 110754664A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- bone
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 46
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 13
- 244000068988 Glycine max Species 0.000 claims abstract description 13
- 241000208688 Eucommia Species 0.000 claims abstract description 12
- 235000020696 epimedium extract Nutrition 0.000 claims abstract description 12
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 11
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 11
- 239000009083 Fructus psoraleae extract Substances 0.000 claims abstract description 10
- 244000235659 Rubus idaeus Species 0.000 claims description 10
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000003687 soy isoflavones Nutrition 0.000 claims description 2
- 241000208689 Eucommia ulmoides Species 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 201000008482 osteoarthritis Diseases 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000037180 bone health Effects 0.000 abstract 2
- 240000007651 Rubus glaucus Species 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 6
- 244000046146 Pueraria lobata Species 0.000 description 5
- 235000010575 Pueraria lobata Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000004097 bone metabolism Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- -1 isopentenyl Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- PNXYAHLYLXMJTQ-UHFFFAOYSA-N 3-(3-methylbut-3-enyl)-2-phenylchromen-4-one Chemical class C(CC(=C)C)C1=C(OC2=CC=CC=C2C1=O)C1=CC=CC=C1 PNXYAHLYLXMJTQ-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 2
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 2
- 235000008209 xanthohumol Nutrition 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000241463 Cullen corylifolium Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 208000008924 Femoral Fractures Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229930008679 prenylflavonoid Natural products 0.000 description 1
- 150000007951 prenylflavonoids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for preventing osteoporosis, and belongs to the field of health-care food. The composition for preventing osteoporosis is prepared from the following raw materials: 10-20 parts of epimedium extract, 5-15 parts of soybean isoflavone, 5-15 parts of hop extract, 2-10 parts of eucommia bark extract, 2-10 parts of fructus psoraleae extract, 2-8 parts of radix puerariae extract and 2-8 parts of raspberry extract. The raw materials are synergistic, the metabolic balance of the bone is reconstructed, the osteoporosis and the osteoarthritis are effectively prevented, the bone health is improved and regulated, and particularly the bone health problem caused by human body aging is solved.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to a composition for preventing osteoporosis.
Background
Osteoporosis is a systemic, metabolic disease of bone characterized by low bone mass and microstructural destruction of bone tissue and can lead to increased bone fragility and susceptibility to fracture. The disease is common in the elderly, but it can occur in all age periods. Osteoporosis can be divided into primary and secondary types. Primary osteoporosis refers to the absence of other diseases that cause the disease; secondary osteoporosis is a decrease in the amount of bone tissue due to various systemic or endocrine metabolic diseases. In addition, localized or generalized osteoporosis may also be classified according to the site of occurrence.
China is the country with the most osteoporosis patients worldwide, and the severity of the osteoporosis is second to that of circulatory system diseases. The data show that the total disease rate of osteoporosis is 12.4% in China, and the total number of people is more than 1.6 hundred million. Experts predict that the number of patients with osteoporosis and low bone mass in China will increase to 2.8 hundred million by 2020. Most patients have no symptoms in the early stage, then have limb weakness and bone joint pain along with gradual loss of human bone, and even fall into fracture after being knocked slightly carelessly.
The medicines clinically used for treating osteoporosis at present mainly comprise nutritional supplements (calcium preparations and vitamin D3), bisphosphates, hormones, fluorides, calcitonin, Chinese patent medicines and the like. Nutritional supplements such as vitamin D and derivatives, which have low absorption conversion rates and are prone to hypercalcemia; the bisphosphonate often causes gastrointestinal side reactions and adverse reactions such as mandibular necrosis, femoral fracture, atrial fibrillation and the like, which leads to poor medication compliance of patients; hormones increase the risk of patients suffering from breast cancer and cervical cancer; the calcitonin can cause allergy and adverse reactions of the nervous system and the digestive system after being taken for a long time; fluoride is prone to cause necrosis of alveolar bone and jaw bone. The Chinese patent medicine mainly takes the medicines for tonifying the liver and the kidney, strengthening the spleen and nourishing the stomach, and activating the blood and promoting the circulation of blood as main components, and has low effective components, so that the development of a product with high effective component content, clear action mechanism, safety and low side effect is urgent.
Disclosure of Invention
The invention aims to solve the technical problem of providing a safe and effective composition for preventing osteoporosis, which is prepared from medicinal and edible and health-care food raw materials. The product concentrates the functional substances in the raw materials, is safe and efficient, and has no side effect. Can reestablish the balance of bone metabolism, effectively prevent osteoporosis and osteoarthritis, and keep away from chronic diseases of rheumatic bone diseases and the like.
In order to solve the technical problems, the technical scheme of the invention is as follows:
the composition for preventing osteoporosis consists of the following components: 10-20 parts of epimedium extract, 5-15 parts of soybean isoflavone, 5-15 parts of hop extract, 2-10 parts of eucommia bark extract, 2-10 parts of fructus psoraleae extract, 2-8 parts of radix puerariae extract and 2-8 parts of raspberry extract.
Further, the composition for preventing osteoporosis consists of the following components: 15 parts of epimedium extract, 10 parts of soybean isoflavone, 10 parts of hop extract, 5 parts of eucommia bark extract, 5 parts of fructus psoraleae extract, 5 parts of radix puerariae extract and 5 parts of raspberry extract.
Furthermore, the content of icariin in the epimedium extract is not less than 10%.
Further, the isoflavone content in the soybean isoflavone is not less than 40%.
Further, the content of flavone in the hop extract is not less than 10%.
Furthermore, the eucommia bark, the fructus psoraleae and the radix puerariae are all proportional extracts.
Further, the composition can be made into tablet, capsule, granule or pill.
After the flavone is modified by isopentenyl, the fat solubility and the affinity to a biological membrane are increased, and a plurality of physiological activities are influenced. Isopentenyl flavones are present in the common Chinese medicines including fructus Psoraleae, herba Epimedii, Glycyrrhrizae radix, and flos Lupuli. Compared with flavonoid compounds, the prenylflavonoids have more outstanding biological activity, mainly comprise the functions of promoting stem cell differentiation, improving osteoporosis, resisting inflammation, regulating immunity and the like.
Icariin is an effective component of epimedium herb, is a good bone induction active component, and can induce mesenchymal stem cells to differentiate to form bone cells. It can not only improve differentiation ability of osteoblast and proliferation ability, but also reduce osteoclast formation and bone resorption, and improve osteoporosis.
Bu Gu Zhi has warm nature and pungent and bitter taste, and has the actions of tonifying kidney and strengthening yang, securing essence and reducing urination, warming spleen and checking diarrhea, absorbing qi and relieving asthma. The fructus Psoraleae extract can obviously promote ALP activity of osteoblast and I type collagen secretion, enhance osteocalcin mRNA expression, and stimulate bone formation, thereby playing the role of resisting osteoporosis.
Soy isoflavones are natural estrogens and are secondary metabolites of soybeans during their growth. Animal experiments show that the Wnt signal path is inactivated due to the low estrogen level in the ovariectomized rats, and the soybean isoflavone can activate the Wnt signal path, so that the differentiation and the proliferation of osteoblasts are promoted.
The isopentenyl flavonoid compounds contained in the hops have plant estrogen-like effect, and can be combined with estrogen receptors in human bodies, thereby playing a role in resisting bone loss. The xanthohumol is a representative component in the compound, and can obviously improve the estrogen level of an ovariectomized mouse, reduce the high bone conversion rate, improve the bone trabecular microenvironment and enhance the bone density. At the osteoblast level, xanthohumol can promote osteoblast proliferation, alkaline phosphatase activity and bone mineralization level, and can also improve the expression of osteopontin, bone sialoprotein and bone morphogenetic protein.
The Chinese herbal medicines such as eucommia bark, kudzuvine root, raspberry and the like are reported in experimental research and have the effects of reducing bone resorption, promoting bone formation and increasing bone density.
The invention has the beneficial effects that:
1. the invention provides a composition for preventing osteoporosis, which is different from the traditional Chinese medicine, adopts a traditional Chinese medicine extract, has definite functional components and high content of active substances.
2. The high-purity isopentenyl flavone can effectively regulate and control signal paths related to stem cells and bone metabolism, promote differentiation and proliferation of osteoblasts, inhibit proliferation of osteoclasts, regulate balance of bone metabolism and keep bones healthy.
3. The product is prepared from raw materials of medicinal and edible food and health-care food, and has no side effect after long-term administration. Besides preventing osteoporosis, the traditional Chinese medicine composition can also supplement female estrogen and relieve female climacteric symptoms without side effects of estrogen treatment.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1
In this embodiment, a composition for preventing osteoporosis comprises the following components: 15 parts of epimedium extract, 10 parts of soybean isoflavone, 10 parts of hop extract, 5 parts of eucommia bark extract, 5 parts of fructus psoraleae extract, 5 parts of radix puerariae extract and 5 parts of raspberry extract.
Example 2
In this embodiment, a composition for preventing osteoporosis comprises the following components: 10 parts of epimedium extract, 10 parts of soybean isoflavone, 8 parts of hop extract, 8 parts of eucommia bark extract, 5 parts of fructus psoraleae extract, 5 parts of kudzu root extract and 4 parts of raspberry extract.
Example 3
In this embodiment, a composition for preventing osteoporosis comprises the following components: 20 parts of epimedium extract, 8 parts of soybean isoflavone, 8 parts of hop extract, 5 parts of eucommia bark extract, 5 parts of malaytea scurfpea fruit extract, 5 parts of kudzu root extract and 5 parts of raspberry extract.
Example 4
In this embodiment, a composition for preventing osteoporosis comprises the following components: 12 parts of epimedium extract, 12 parts of soybean isoflavone, 10 parts of hop extract, 5 parts of eucommia bark extract, 6 parts of fructus psoraleae extract, 3 parts of kudzu root extract and 5 parts of raspberry extract.
Example 5
In this embodiment, a composition for preventing osteoporosis comprises the following components: 12 parts of epimedium extract, 9 parts of soybean isoflavone, 10 parts of hop extract, 5 parts of eucommia bark extract, 6 parts of fructus psoraleae extract, 4 parts of kudzu root extract and 2 parts of raspberry extract. Sieving the above materials with 2 parts of xylitol and 20 parts of resistant dextrin, mixing, adding 80% ethanol to obtain soft material, wet granulating, drying, sieving with 18 mesh sieve, grading, adding 1 part of magnesium stearate, mixing, and pressing into 0.6 g/tablet.
Claims (7)
1. A composition for preventing osteoporosis, comprising: 10-20 parts of epimedium extract, 5-15 parts of soybean isoflavone, 5-15 parts of hop extract, 2-10 parts of eucommia bark extract, 2-10 parts of fructus psoraleae extract, 2-8 parts of radix puerariae extract and 2-8 parts of raspberry extract.
2. The composition for preventing osteoporosis of claim 1, which comprises: 15 parts of epimedium extract, 10 parts of soybean isoflavone, 10 parts of hop extract, 5 parts of eucommia bark extract, 5 parts of fructus psoraleae extract, 5 parts of radix puerariae extract and 5 parts of raspberry extract.
3. A composition as in claim 1 or 2 wherein the icariin content of the epimedium extract is not less than 10%.
4. A composition according to claim 1 or 2, wherein the isoflavone content in the soy isoflavones is not less than 40%.
5. A composition according to claim 1 or 2, wherein the hop extract has a content of flavone of not less than 10%.
6. The composition according to claim 1 or 2, wherein the eucommia ulmoides, the fructus psoraleae and the radix puerariae are proportional extracts.
7. The composition according to claim 1 or 2, wherein the composition is formulated as a tablet, capsule, granule or pill.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911235880.XA CN110754664A (en) | 2019-12-05 | 2019-12-05 | Composition for preventing osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911235880.XA CN110754664A (en) | 2019-12-05 | 2019-12-05 | Composition for preventing osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110754664A true CN110754664A (en) | 2020-02-07 |
Family
ID=69341040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911235880.XA Pending CN110754664A (en) | 2019-12-05 | 2019-12-05 | Composition for preventing osteoporosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110754664A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030010352A (en) * | 2001-07-26 | 2003-02-05 | 칼리지파마(주) | Health foods composition including Eucommia ulmoides Oliver and Isoflavone |
CN103751529A (en) * | 2014-02-11 | 2014-04-30 | 王雪雁 | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method thereof |
CN103751516A (en) * | 2014-01-06 | 2014-04-30 | 薛清佩 | Chinese herbal medicine formula for treating osteoporosis and preparation method thereof |
CN109549969A (en) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | A kind of flavonoids health care product and preparation method thereof for preventing and treating osteoporosis |
-
2019
- 2019-12-05 CN CN201911235880.XA patent/CN110754664A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030010352A (en) * | 2001-07-26 | 2003-02-05 | 칼리지파마(주) | Health foods composition including Eucommia ulmoides Oliver and Isoflavone |
CN103751516A (en) * | 2014-01-06 | 2014-04-30 | 薛清佩 | Chinese herbal medicine formula for treating osteoporosis and preparation method thereof |
CN103751529A (en) * | 2014-02-11 | 2014-04-30 | 王雪雁 | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method thereof |
CN109549969A (en) * | 2017-09-26 | 2019-04-02 | 东莞自然衡健康科技有限公司 | A kind of flavonoids health care product and preparation method thereof for preventing and treating osteoporosis |
Non-Patent Citations (1)
Title |
---|
龚剑秋等: "覆盆子抗骨质疏松化学组成及抗骨质疏松活性成分研究", 《中华中医药学刊》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Therapeutic potential and outlook of alternative medicine for osteoporosis | |
CN101428056A (en) | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof | |
CN101288686A (en) | Health preparation for increasing bone density and preparation method thereof | |
US20050260285A1 (en) | Healthy prostate formula | |
CN102846906B (en) | Medicament for treating premature ovarian failure and preparation method thereof | |
CN106938005A (en) | A kind of Chinese medicine composition for being used to treat osteoporosis | |
CN104547750A (en) | Traditional Chinese medicine composition for treating senile osteoporosis | |
CN103877247B (en) | Medicine being used for the treatment of decubital ulcer and preparation method thereof | |
WO2017005159A1 (en) | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and use thereof | |
CN108272943A (en) | A kind of pharmaceutical composition and preparation method thereof for treating osteoporotic fracture | |
CN103751762B (en) | A kind ofly skin cell is promoted to recombinate and can the product of slow down aging | |
CN103405755A (en) | Pharmaceutical composition for treating primary osteoporosis | |
CN103349674A (en) | Tortoise shell rana japonica oil composition for increasing bone density and preventing osteoporosis | |
CN110754664A (en) | Composition for preventing osteoporosis | |
US11975052B2 (en) | Compound composition for improving bone health and preparation and application thereof | |
CN109381491B (en) | Composition for preventing and treating osteoporosis and preparation method and application thereof | |
CN102793849A (en) | Traditional Chinese medicine for treating middle and old aged osteoporosis | |
CN106860656A (en) | It is a kind of to treat Chinese medicine composition of osteoporosis and its preparation method and application | |
CN105596410A (en) | Mongolian medicine for treating bone fracture | |
CN109289017A (en) | For clearing up the composition and preparation method of blood vessel and blood | |
CN109549969A (en) | A kind of flavonoids health care product and preparation method thereof for preventing and treating osteoporosis | |
Jethwa | Alternative Medical Therapy | |
KR102592954B1 (en) | Manufacturing method for composition promoting bone density improving | |
CN1330325C (en) | Medicine for preventing and curing osteoporosis and its preparing method | |
CN102988937B (en) | Traditional Chinese medicine composition for treating enuresis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 100089 room 127, 1f, No. 7, Fengxian Middle Road, Haidian District, Beijing Applicant after: Beikexin (Beijing) stem cell Medical Research Institute Co.,Ltd. Address before: 100000 Room 308, floor 3, building 5, No. 7, Qingta Dongli, Fengtai Road, Fengtai District, Beijing Applicant before: Beijing kainengting Stem Cell Technology Research Institute Co.,Ltd. |
|
CB02 | Change of applicant information |